186 related articles for article (PubMed ID: 32843425)
61. Genomic Profiling of T-Cell Neoplasms Reveals Frequent
Greenplate A; Wang K; Tripathi RM; Palma N; Ali SM; Stephens PJ; Miller VA; Shyr Y; Guo Y; Reddy NM; Kozhaya L; Unutmaz D; Chen X; Irish JM; Davé UP
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30079384
[TBL] [Abstract][Full Text] [Related]
62. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
63. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
[TBL] [Abstract][Full Text] [Related]
64. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
65. Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor.
Zyuz'kov GN; Zhdanov VV; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM
Bull Exp Biol Med; 2016 Dec; 162(2):240-243. PubMed ID: 27905037
[TBL] [Abstract][Full Text] [Related]
66. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Hsu L; Armstrong AW
J Immunol Res; 2014; 2014():283617. PubMed ID: 24883332
[TBL] [Abstract][Full Text] [Related]
67. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
[TBL] [Abstract][Full Text] [Related]
68. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
Mullighan CG
Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
[TBL] [Abstract][Full Text] [Related]
69. Role of JAK1, JAK2, and JAK3 in Functional Stimulation of Mesenchymal Precursor Cells by Alkaloid Songorine.
Zyuz'kov GN; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM; Chaikovskii AV; Agafonov VI; Zhdanov VV
Bull Exp Biol Med; 2017 Aug; 163(4):443-446. PubMed ID: 28853089
[TBL] [Abstract][Full Text] [Related]
70. Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia.
Yagi K; Shimada A; Sendo T
Eur J Pharmacol; 2018 Apr; 825():28-33. PubMed ID: 29458040
[TBL] [Abstract][Full Text] [Related]
71. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
73. Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT
Belman JP; Meng W; Wang HY; Li J; Strauser HT; Rosenfeld AM; Zhang Q; Prak ETL; Wasik M
Cold Spring Harb Mol Case Stud; 2020 Feb; 6(1):. PubMed ID: 31776129
[TBL] [Abstract][Full Text] [Related]
74. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
75. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.
Tavakolpour S
Dermatol Ther; 2018 Sep; 31(5):e12696. PubMed ID: 30207045
[TBL] [Abstract][Full Text] [Related]
76. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
77. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
78. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
79. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Tanaka Y
J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
[TBL] [Abstract][Full Text] [Related]
80. IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity.
Das Gupta D; Paul C; Samel N; Bieringer M; Staudenraus D; Marini F; Raifer H; Menke L; Hansal L; Camara B; Roth E; Daum P; Wanzel M; Mernberger M; Nist A; Bauer UM; Helmprobst F; Buchholz M; Roth K; Bastian L; Hartmann AM; Baldus C; Ikuta K; Neubauer A; Burchert A; Jäck HM; Klein M; Bopp T; Stiewe T; Pagenstecher A; Lohoff M
Cell Death Differ; 2022 Nov; 29(11):2163-2176. PubMed ID: 35459909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
